Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes (January 2021).


Journal

Clinical medicine (London, England)
ISSN: 1473-4893
Titre abrégé: Clin Med (Lond)
Pays: England
ID NLM: 101092853

Informations de publication

Date de publication:
05 2021
Historique:
entrez: 18 5 2021
pubmed: 19 5 2021
medline: 21 5 2021
Statut: ppublish

Résumé

Sodium glucose co-transporter 2 (SGLT2) inhibitors are now an established class of medications for the treatment of type 2 diabetes (T2D), no longer reserved for use by specialists in diabetes. They are being used increasingly for their cardiac and renal benefits by primary care, cardiology and renal teams for indications in parallel with diabetes care as part of holistic management. This guidance provides essential information on SGLT therapy, including the main advantages and the important risks of which healthcare professionals should be aware.

Identifiants

pubmed: 34001571
pii: 21/3/204
doi: 10.7861/clinmed.2021-0045
pmc: PMC8140708
doi:

Substances chimiques

Hypoglycemic Agents 0
Sodium-Glucose Transporter 2 Inhibitors 0
Symporters 0
Sodium 9NEZ333N27
Glucose IY9XDZ35W2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

204-210

Informations de copyright

© Royal College of Physicians 2021. All rights reserved.

Références

N Engl J Med. 2020 Oct 8;383(15):1436-1446
pubmed: 32970396
N Engl J Med. 2020 Oct 8;383(15):1413-1424
pubmed: 32865377
Rev Endocr Metab Disord. 2020 Dec;21(4):613-629
pubmed: 32128655
Nat Rev Dis Primers. 2020 May 14;6(1):40
pubmed: 32409703
J Am Soc Nephrol. 2013 Feb;24(2):302-8
pubmed: 23362314
Diabetes Care. 2020 Feb;43(2):487-493
pubmed: 31857443
Diabet Med. 2011 May;28(5):508-15
pubmed: 21255074
Diabetes Care. 2020 Jan;43(Suppl 1):S14-S31
pubmed: 31862745
Lancet. 2019 Jan 5;393(10166):31-39
pubmed: 30424892
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Lancet Diabetes Endocrinol. 2018 May;6(5):349-352
pubmed: 29483059
Curr Med Chem. 2020;27(39):6682-6702
pubmed: 31663470
N Engl J Med. 2020 Oct 8;383(15):1425-1435
pubmed: 32966714
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829

Auteurs

Umesh Dashora (U)

Conquest Hospital, St Leonards-on-Sea, UK u.dashora@nhs.net.

Robert Gregory (R)

University Hospitals of Leicester NHS Trust, Leicester, UK.

Peter Winocour (P)

East and North Hertfordshire NHS Trust, Stevenage, UK.

Ketan Dhatariya (K)

Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK.

Susannah Rowles (S)

Pennine Acute Hospitals NHS Trust, Manchester, UK.

Andrew Macklin (A)

Dorset County Hospital NHS Foundation Trust, Dorchester, UK.

Gerry Rayman (G)

East Suffolk and North East Essex NHS Foundation Trust, Ipswich, UK.

Dinesh Nagi (D)

Pinderfields Hospital, Wakefield, UK.

Katie Whitehead (K)

The Hollies Medical Centre, Sheffield, UK.

Hannah Beba (H)

County Durham and Darlington NHS Foundation Trust, Durham, UK.

Parijat De (P)

Sandwell and West Birmingham Hospital NHS Trust, Sandwell, UK.

Dipesh C Patel (DC)

University College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH